Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Recruiting · NCT04070040 · Registry updated 2024-10-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) | primary central nervous system lymphoma | Recruiting | Phase 2 | 2024-10-15 | NCT04070040 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Sanbo Brain Hospital | 16 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sanbo Brain Hospital Capital Medical University | Beijing | China | 2 |